Aiming at evaluating the effectiveness and safety of Guizhi Fuling Wan or Keishibukuryogan (GZFL) on prostate diseases, to provide available synthesized evidence for clinical application.
Methods:
Randomized controlled trials (RCTs) were identified from English, Chinese, Japanese, and Korean electronic databases, the search date ranged from the inception of databases to July 2024. Rev-Man 5.4.1 software was applied in the analysis of extracted data.
Results:
23 studies were included in the meta-analysis, 12 studies on chronic prostatitis(CP) and 11 studies on benign prostatic hyperplasia (BPH). The synthesized results showed that GZFL had a significantly higher effective rate compared to the control group both in BPH (risk difference [RD] = 0.14, 95% confidence interval [CI] [0.10, 0.18], p < 0.00001) and CP (RD = 0.19, 95% CI [0.14, 0.23], p < 0.00001). It reduced the International Prostate Symptom score (mean difference [MD] = −3.19, 95% CI [−5.35, −1.02], p = 0.004) and NIH Chronic Prostatitis Symptom Index score (MD = −4.09, 95% CI [−5.04, −3.15], p < 0.00001), It also had a significant effect on reducing postvoid residual urine (MD = −6.73, 95% CI [−10.12, −3.33], p = 0.0001), prostate volume (MD = −2.59, 95% CI [−4.39, −0.80], p = 0.005), and increasing maximum urinary flow rate (MD = 1.61, 95% CI [1.11, 2.10], P < 0.00001). A few studies have also reported its therapeutic effects on prostate cancer. No severe adverse effects were reported.
Conclusion:
GZFL is effective and safe for BPH and CP in alleviating symptoms, improving scale scores. Rigorously designed clinical trials are necessary for further clinical application.
LinTY, ChenIH, WengHY, et al.Association between chronic prostatitis and the subsequent benign prostatic hyperplasia: A population-based national cohort study. World J Urol, 2024; 42(1):126; doi: 10.1007/s00345-024-04820-w
2.
JungG, KimJK, KimH, et al.The association between prostatitis and risk of prostate cancer: A National Health Insurance Database study. World J Urol, 2022; 40(11):2781–2787; doi: 10.1007/s00345-022-04165-2
3.
MiH, ChenK, MoZN. Epidemiological characteristics of chronic prostatitis in China. National Journal of Andrology, 2012; 18(07):579–582; doi: 10.13263/j.cnki.nja.2012.07.005
4.
KriegerJN, LeeSWH, JeonJ, et al.Epidemiology of prostatitis: New evidence for a world-wide problem. Int J Antimicrob Agents, 2008; 31(Suppl 1):S85–S90.
5.
RobertsRO, JacobsonDJ, GirmanCJ, et al.Low agreement between previous physician diagnosed prostatitis and national institutes of health chronic prostatitis symptom index pain measures. J Urol, 2004; 171(1):279–283; doi: 10.1097/01.ju.0000100088.70887.29
6.
LaunerBM, McVaryKT, RickeWA, et al.The rising worldwide impact of benign prostatic hyperplasia. BJU Int, 2021; 127(6):722–728; doi: 10.1111/bju.15286
7.
SungH, FerlayJ, SiegelRL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021; 71(3):209–249; doi: 10.3322/caac.21660
8.
SiegelRL, GiaquintoAN, JemalA. Cancer statistics, 2024. CA. CA Cancer J Clin, 2024; 74(1):12–49; doi: 10.3322/caac.21820
9.
LaiH, GereauRW, LuoY, et al.Animal models of urologic chronic pelvic pain syndromes: Findings from the multidisciplinary approach to the study of chronic pelvic pain research network. Urology, 2015; 85(6):1454–1465; doi: 10.1016/j.urology.2015.03.007
10.
BharuchaAE, LeeTH. Anorectal and pelvic pain. Mayo Clin Proc, 2016; 91(10):1471–1486; doi: 10.1016/j.mayocp.2016.08.011
LanganRC. Benign prostatic hyperplasia. Prim Care, 2019; 46(2):223–232; doi: 10.1016/j.pop.2019.02.003
13.
AdamianL, UritsI, OrhurhuV, et al.A comprehensive review of the diagnosis, treatment, and management of urologic chronic pelvic pain syndrome. Curr Pain Headache Rep, 2020; 24(6):27; doi: 10.1007/s11916-020-00857-9
14.
MiernikA, GratzkeC. Current treatment for benign prostatic hyperplasia. Dtsch Arztebl Int, 2020; 117(49):843–854; doi: 10.3238/arztebl.2020.0843
15.
TrofimenkoV, MyersJB, BrantWO. Post-prostatectomy incontinence: How common and bothersome is it really? Sex Med Rev, 2017; 5(4):536–543; doi: 10.1016/j.sxmr.2017.05.001
16.
ZhouY, WangJ-H, HanJ-P, et al.Dihydroartemisinin ameliorates chronic nonbacterial prostatitis and epithelial cellular inflammation by blocking the E2F7/HIF1α pathway. Inflamm Res, 2022; 71(4):449–460; doi: 10.1007/s00011-022-01544-8
17.
ZhouH, HouT, ShenA, et al.Elucidation of active components and target mechanism in Jinqiancao granules for the treatment of prostatitis and benign prostatic hyperplasia. J Ethnopharmacol, 2024; 328:118068; doi: 10.1016/j.jep.2024.118068
18.
WeiY, ZhuM, ChenY, et al.Network pharmacology and experimental evaluation strategies to decipher the underlying pharmacological mechanism of Traditional Chinese Medicine CFF-1 against prostate cancer. Aging (Albany NY), 2024; 16(6):5387–5411; doi: 10.18632/aging.205654
19.
LiuH, WangZ, XieQ, et al.Ningmitai capsules have anti-inflammatory and pain-relieving effects in the chronic prostatitis/chronic pelvic pain syndrome mouse model through systemic immunity. Front Pharmacol, 2022; 13:949316; doi: 10.3389/fphar.2022.949316
20.
ZangL, TianF, YaoY, et al.Qianliexin capsule exerts anti-inflammatory activity in chronic non-bacterial prostatitis and benign prostatic hyperplasia via NF-κB and inflammasome. J Cell Mol Med, 2021; 25(12):5753–5768; doi: 10.1111/jcmm.16599
21.
WuZ, LiuC, PengY, et al.Traditional Chinese herbal medicine retention enema combined with perineal massage (THREM): A promising therapeutic strategy for refractory chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Transl Androl Urol, 2024; 13(5):759–768; doi: 10.21037/tau-23-386
22.
LiuY, ShaoR, SuoT, et al.Traditional Chinese Medicine Danzhi qing’e decoction inhibits inflammation-associated prostatic hyperplasia via inactivation of ERK1/2 signal pathway. J Ethnopharmacol, 2023; 309:116354; doi: 10.1016/j.jep.2023.116354
23.
HnitSST, YaoM, XieC, et al.Transcriptional regulation of G2/M regulatory proteins and perturbation of G2/M Cell cycle transition by a traditional Chinese medicine recipe. J Ethnopharmacol, 2020; 251:112526; doi: 10.1016/j.jep.2019.112526
24.
YoshihisaY, FuruichiM, RehmanMU, et al.The traditional Japanese formula Keishibukuryogan inhibits the production of inflammatory cytokines by dermal endothelial cells. Mediators Inflamm, 2010; 2010:804298; doi: 10.1155/2010/804298
25.
LeeCL, ShinHK, LeeJY, et al.Combination therapy with tamsulosin and traditional herbal medicine for lower urinary tract symptoms due to benign prostatic hyperplasia: A double-blinded, randomized, pilot clinical trial. Int J Urol, 2022; 29(6):503–509; doi: 10.1111/iju.14821
26.
KongLW. The study on the distribution regulaotion of TCM Syndrome type and Constitution of chronic prostatitis patients in Kunming. Yunnan University of Traditional Chinese Medicine, 2020; doi: 10.27460/d.cnki.gyzyc.2020.000253
27.
HuHX, LiuHY, XiaK, et al.Correlation between TCM syndromes and clinical indices of benign prostatic hyperplasia. Liaoning Journal of Traditional Chinese Medicine, 2014; 41(11):2347–2349; doi: 10.13192/j.issn.1000-1719.2014.11.031
28.
The Andrology Division of the China Association of Chinese Medicine Informatics. Guidelines for multidisciplinary diagnosis and treatment of benign prostatic hyperplasia with integrated traditional Chinese and western medicine (2022 Edition). Chinese Journal of Andrology, 2022; 36(02):96–102.
29.
Andrology Professional Committee of the Chinese Association of Integrative Medicine. Guidelines for the diagnosis and treatment of chronic prostatitis with integrated traditional Chinese and Western Medicine. Chinese Journal of Andrology, 2023; 37(01):3–17.
30.
ParkBK, KimYH, KimYR, et al.Antineuroinflammatory and neuroprotective effects of Gyejibokryeong-Hwan in Lipopolysaccharide-Stimulated BV2 Microglia. Evid Based Complement Alternat Med, 2019; 2019:7585896–7585814; doi: 10.1155/2019/7585896
31.
TanakaR, ShibataH, SugimotoN, et al.Application of a quantitative 1H-NMR method for the determination of paeonol in Moutan cortex, Hachimijiogan and Keishibukuryogan. J Nat Med, 2016; 70(4):797–802; doi: 10.1007/s11418-016-1003-3
32.
SatomiH, MoriY, MakinoB, et al.Clustering analysis of Keishibukuryogan formulas by use of self-organizing maps. Chem Pharm Bull (Tokyo), 2010; 58(11):1497–1501; doi: 10.1248/cpb.58.1497
33.
KimJH, SeoCS, ShinHK. Development of validated determination of the eleven marker compounds in Gyejibokryeong-hwan for the quality assessment using HPLC analysis. Arch Pharm Res, 2015; 38(1):52–62; doi: 10.1007/s12272-014-0363-z
34.
MatsubaraY, MatsumotoT, SekiguchiK, et al.Oral administration of the Japanese traditional medicine Keishibukuryogan-ka-yokuinin decreases reactive oxygen metabolites in rat plasma: Identification of chemical constituents contributing to antioxidant activity. Molecules, 2017; 22(2):256; doi: 10.3390/molecules22020256
35.
JeonWY, JinSE, SeoCS, et al.Safety assessment of Gyejibokryeong-hwan water extract: Study of acute and subacute toxicity, and influence on drug metabolizing enzymes. J Ethnopharmacol, 2019; 240:111913; doi: 10.1016/j.jep.2019.111913
36.
GaoJ, YangJ, LuZ, et al.The multiple pharmacologic functions and mechanisms of action of Guizhi Fuling Formulation. Evid Based Complement Alternat Med, 2022; 2022:6813421; doi: 10.1155/2022/6813421
37.
LeeAY, LeeJY, ChunJM. Exploring the mechanism of Gyejibokryeong-hwan against atherosclerosis using network pharmacology and molecular docking. Plants (Basel), 2020; 9(12):1750; doi: 10.3390/plants9121750
38.
TanakaK, ChibaK, NaraK. A review on the mechanism and application of Keishibukuryogan. Front Nutr, 2021; 8:760918; doi: 10.3389/fnut.2021.760918
39.
GongHH, QianLJ. The clinical effect of cold and warm treatment on chronic benign prostatic hyperplasia and the influence on IPSS scores. Chinese Archives of Traditional Chinese Medicine, 2014; 32(3):675–677; doi: 10.13193/j.issn.1673-7717.2014.03.078
40.
GaoJG, SunXQ, HouSC, et al.Modified Guizhi Fuling Wan combined with Doxazosin for treating lower urinary tract symptoms in 34 patients with benign prostatic hyperplasia. Journal of Traditional Chinese Medicine, 2011; 52(07):603–604; doi: 10.13288/j.11-2166/r.2011.07.039
41.
LiuDL. Clinical observation of modified Guizhi Fuling Wan treatment in 63 cases of benign prostatic hyperplasia. Shanxi Medical Journal, 2019; 48(20):2506–2507.
42.
ZhanYS. Treatment of 42 cases of benign prostatic hyperplasia with Taohes Chengqi decoction combined with Guizhi Fuling Wan. Journal of Anhui TCM College, 2006; 25(5):20.
43.
YangGY. Treatment of 47 cases of benign prostatic hyperplasia with modified Shengjiang powder combined with Guizhi Fuling Wan. Nei Mongol Journal of Traditional Chinese Medicine, 2014; 33(19):7–8; doi: 10.16040/j.cnki.cn15-1101.2014.19.045
44.
JingMF, FengXM. Observation on the efficacy of modified Guizhi Fuling Wan in the treatment of 42 cases of benign prostatic hyperplasia. Nei Mongol Journal of Traditional Chinese Medicine, 2016; 35(08):49; doi: 10.16040/j.cnki.cn15-1101.2016.08.051
45.
LuoS. Clinical observation of Jianpi Bushen Huoxue Decoction combined with Guizhi Fuling Wan in the treatment of prostatic hyperplasia. Guangming Journal of Chinese Medicine, 2023; 38(23):4600–4602.
46.
LiJL. Observation on the efficacy of Shengjiangsan combined with Guizhi Fuling Wan in the treatment of benign prostatic hyperplasia. Women’s Health Research, 2015; 2015(20):191.
47.
YuSC, HeHB. The effects of tamsulosin hydrochloride controlled-release tablets combined with Guizhi Fuling Wan on urodynamics in benign prostatic hyperplasia. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2017; 26(6):631–633.
48.
LiuC, LiL. Treatment of benign prostatic hyperplasia with Zhenwu decoction combined with Guizhi Fuling Wan. China Practical Medicine, 2010; 5(5):162–163; doi: 10.14163/j.cnki.11-5547/r.2010.05.026
49.
HuangXD, WangQH, HuangSH. Observation on the clinical effect of modified Guizhi Fuling Wan combined with finasteride in the treatment of benign prostatic hyperplasia. Journal of Frontiers of Medicine, 2022; 12(10):121–123.
50.
ZhangGQ. Treatment of 42 cases of type IIIA prostatitis (damp-heat with blood stasis pattern) with modified Guizhi Fuling decoction combined with Zhuling decoction. Traditional Chinese Medicine Research, 2017; 30(07):41–43.
51.
ZhangGQ. Guizhi Fuling decoction combined with Zhuling Decoction and Tamsulosin Sustained-Release Capsules in the treatment of 41 cases of benign prostatic hyperplasia. Henan Traditional Chinese Medicine, 2017; 37(08):1338–1340.
52.
WuCL, ChenXJ, FanYY, et al.Dachaohu Decoction combined with Guizhi Fuling Wan in the treatment of 52 cases of type III chronic prostatitis with damp-heat and blood stasis obstruction. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine, 2021; 31(04):342–344.
53.
XieB. Observation on the efficacy of modified Guizhi Fuling Wan in the treatment of chronic prostatitis. Chinese Journal of Clinical Rational Drug Use, 2014; 7(4A):19–20; doi: 10.15887/j.cnki.13-1389/r.2014.10.118
54.
WangB. Treatment of 45 cases of chronic prostatitis with modified Guizhi Fuling Wan. Forum on Traditional Chinese Medicine, 2004; 19(03):8.
55.
LiuJR, LiuSY. Observation of the efficacy of Yi Yi Fu Zi Bai Jiang San combined with Guizhi Fuling Wan in treating chronic prostatitis of the damp-heat and blood stasis sydrome. Journal of Clinical Medical, 2018; 5(37):165–166; doi: 10.16281/j.cnki.jocml.2018.37.124
56.
WangZL. Treatment of 120 cases of chronic prostatitis of damp-heat and blood stasis syndrome with Yi Yi Fu Zi Bai Jiang San combined with Guizhi Fuling Wan. Journal of Sichuan of Traditional Chinese Medicine, 2007; 25(10):48–49.
57.
LanS. Treatment of 80 cases of chronic prostatitis with modified Jinpu decoction and Guizhi Fuling Wan. Chinese Journal of Ethnomedicine and Ethnopharmacy, 2013; 22(6):74.
58.
LongXZ, ChenQH. Treatment of 60 cases of type III prostatitis with modified Guizhi Fuling Wan. Guiding Journal of Traditional Chinese Medicine and Pharmacy, 2014; 20(04):114–115; doi: 10.13862/j.cnki.cn43-1446/r.2014.04.050
59.
HuSX. Treatment of 60 cases of chronic nonbacterial prostatitis with modified Guizhi Fuling Wan. Liaoning Journal of Traditional Chinese Medicine, 2009; 36(09):1513–1514; doi: 10.13192/j.ljtcm.2009.09.77.hushx.028
60.
ZhaoT. Clinical study on Guizhi Fuling Wan combined with auricular acupressure in the treatment of type IIIb prostatitis (damp-heat and blood stasis sydrome). Beijing University of Traditional Chinese Medicine, 2021; doi: 10.26973/d.cnki.gbjzu.2021.000138
61.
JiaXY, MenB, JingRY, et al.Efficacy of modified Guizhi Fuling Wan in treating patients with chronic prostatitis and its mechanism of inflammation regulation. World Journal of Integrated Traditional and Western Medicine, 2024; 19(05):957–962; doi: 10.13935/j.cnki.sjzx.240517
62.
KogaN, MoriyaF, WakiK, et al.Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine. Cancer Sci, 2017; 108(12):2326–2332; doi: 10.1111/cas.13397
63.
IkeuchiT. Clinical studies on chronic prostatitis and prostatitis-like syndrome(4) the kampo treatment for intractable prostatitis. Acta Urol, 1990; 36(7):801–806.
64.
OhtsukaK. Efficacy of combination therapy with Cho-rei-to and Keishi-bukuryo-gan in patients with chronic prostatism. Medicine and Pa, 2009; 62(6):1051–1054.
65.
IkeuchiT, UenoM, YogiS, et al.Clinical studies on chronic prostatitis and prostatitis-like syndrome(5) evaluation of prostatitis complicated by anal disease. Acta Urol, 1991; 37:1677–1682.
66.
LeeSH, LeeJH, HongM, et al.A Case Report of Chronic Prostatitis/Chronic Pelvic Pain Syndrome(CP/CPPS) treated with Gyejibokryeong-hwan. J Korean Med, 2020; 41(1):117–125; doi: 10.13048/jkm.20009
67.
ShigeharaK, IzumiK, NakashimaK, et al.Efficacy and safety of keishibukuryogan, a traditional Japanese Kampo medicine, for hot flashes in prostate cancer patients receiving androgen deprivation therapy. Transl Androl Urol, 2020; 9(6):2533–2540; doi: 10.21037/tau-20-901
68.
ZhangX. Significant tumor reduction with traditional chinese medicine in a patient with advanced prostate cancer: A case report. Am J Mens Health, 2022; 16(5):15579883221130854; doi: 10.1177/15579883221130854
69.
ZhaoH, DuanP. Treatment of 60 cases of prostatic hyperplasia with modified Guizhi Fuling Pill. World Latest Medicine Information, 2015; 15(04):130.
70.
TerawakiK, NoguchiM, YuzuriharaM, et al.Keishibukuryogan, a traditional japanese medicine, inhibits platelet aggregation in guinea pig whole blood. Evid Based Complement Alternat Med, 2015; 2015:295706–295708; doi: 10.1155/2015/295706
71.
ZhangTC, LiuY, ZhangMY. Research progress on the pharmacology of Guizhi Fuling Wan. Journal of Liaoning University of Traditional Chinese Medicine, 2024:1–10.
72.
FanZ, LiuJ, WangX, et al.Paeoniae radix rubra: A review of ethnopharmacology, phytochemistry, pharmacological activities, therapeutic mechanism for blood stasis syndrome, and quality control. Chem Biodivers, 2024; 21(8):e202401119; doi: 10.1002/cbdv.202401119
73.
HirayamaA, TomitaT, NishidaT, et al.Live-imaging analysis of target vessels and nitric oxide production associated with Gosha-Jinki-Gan and Keishi-Bukuryo-Gan: Two herbal preparations with clinically proven blood flow-improving effects but with different traditional clinical indicative patterns. Evid Based Complement Alternat Med, 2022; 2022:3821345; doi: 10.1155/2022/3821345
74.
LitwinMS, McNaughton-CollinsM, FowlerFJ, et al.The national institutes of health chronic prostatitis symptom index: Development and validation of a new outcome measure. J Urol, 1999; 162(2):369–375; doi: 10.1016/s0022-5347(05)68562-x
75.
LiuD, ChenYF, LiuZJ, et al.Network pharmacology and experimental study of modified Guizhi Fuling Wan in the treatment of benign prostatic hyperplasia. Natural Product Research and Development, 2022; 34(07):1234–1249; doi: 10.16333/j.1001-6880.2022.7.017
76.
WangXT, HaoL, ZhouXG, et al.Study on the effect and mechanism of Guizhi Fuling Wan on rats with prostatic hyperplasia model. Chinese Journal of Andrology, 2021; 35(02):31–35.
77.
YangAP, LiuH, FanLX, et al.Exploring the mechanism of Guizhi Fuling Wan in treating benign prostatic hyperplasia based on network pharmacology. Journal of Chinese Medicinal Materials, 2020; 43(06):1456–1461; doi: 10.13863/j.issn1001-4454.2020.06.033
78.
ChenJT, ShirakiM. Menopausal hot flash and calciotonin gene-related peptide; effect of Keishi-bukuryo-gan, a kampo medicine, related to plasma calciotonin gene-related peptide level. Maturitas, 2003; 45(3):199–204; doi: 10.1016/S0378-5122(03)00128-2
79.
NieA, ChaoY, ZhangX, et al.Phytochemistry and pharmacological activities of WolfiPoria (F.A. Wolf) Ryvarden & Gilb. Front Pharmacol, 2020; 11:505249; doi: 10.3389/fphar.2020.505249
80.
LinMY, ChiangSY, LiYZ, et al.Anti-tumor effect of Radix Paeoniae Rubra extract on mice bladder tumors using intravesical therapy. Oncol Lett, 2016; 12(2):904–910; doi: 10.3892/ol.2016.4698
81.
LiuY, WuH, ZhangZ, et al.Traditional use, phytochemistry, pharmacology, toxicology and clinical applications of persicae semen: A review. Chin J Integr Med, 2024; 30(12):1137–1147; doi: 10.1007/s11655-024-3815-4
82.
LiuJ, ZhangQ, LiRL, et al.The traditional uses, phytochemistry, pharmacology and toxicology of Cinnamomi ramulus: A review. J Pharm Pharmacol, 2020; 72(3):319–342; doi: 10.1111/jphp.13189
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
